In addition, in a phase II clinical trial, dovitinib, a pan-inhibitor of FGFR1-3, VEGFR, and PDGFR, combined with fulvestrant, increased PFS in postmenopausal women with HER2-, HR+ breast cancer [224]. Here, ERBB2 is linked to breast carcinoma.